THOUSAND OAKS (dpa-AFX) - The U.S. Food and Drug Administration has approved
Amgen Inc.'s Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to
Soliris (eculizumab), developed by British drug major AstraZeneca's Rare Disease
unit Alexion Pharmaceuticals, to treat two rare diseases.

Soliris is a medicine used to treat adults and children with paroxysmal
nocturnal haemoglobinuria or PNH and atypical haemolytic uraemic syndrome or
aHUS.

Bkemv, a monoclonal antibody, is now approved for the treatment of patients with
PNH to reduce hemolysis; and of patients with aHUS to inhibit
complement-mediated thrombotic microangiopathy.

In the U.S., a disease is considered rare if it affects fewer than 200,000
people. The conditions PNH and aHUS are rare diseases characterized by the
breakdown of red blood cells.

Interchangeable biosimilars are biosimilars that have been shown to meet other
requirements under the law and may be substituted for the reference product
without consulting the prescriber.

The substitution may occur at the pharmacy, subject to state pharmacy laws which
vary by state, similar to generic drug substitution for brand name drugs.

Bkemv, as an interchangeable biosimilar, is highly similar with no clinically
meaningful differences to Soliris. It has the same safety warnings and is
expected to have the same adverse reactions as Soliris.

Bkemv binds to the complement C5 protein and inhibits activation of the
complement system, a part of the body's immune system. This binding prevents the
breakdown of red blood cells in the bloodstream (intravascular hemolysis) in
patients with PNH and aHUS.

The agency noted that Bkemv is available only through a restricted program
called the Bkemv Risk Evaluation and Mitigation Strategy or REMS. It is a drug
safety program that the FDA can require for certain medications with serious
safety concerns to help ensure the benefits of the medication outweigh its
risks.

Sarah Yim, director of the Office of Therapeutic Biologics and Biosimilars in
the FDA's Center for Drug Evaluation and Research, said, 'Many rare conditions
are life-threatening, and many do not have treatments. The FDA is committed to
help facilitate the development of safe and effective interchangeable biosimilar
treatments that can expand access for individuals with rare diseases whose
current treatment options are limited.'

Bkemv is the 53rd approved biosimilar in the U.S. The FDA has approved 13 of
these as interchangeable biosimilars.

For More Such Health News, visit rttnews.com



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX